| Bioactivity | CTP-NBD is a cell permeable specific NFκB peptide inhibitor. CTP-NBD could be used in colitis study[1][2] |
| Invitro | CTP-NBD (200 μM, 6 h) 在 HCT116 细胞中可抑制 TNF-α 诱导的荧光素酶活性[1].CTP-NBD (200 μM, 6 h) 在 RAW264.7 细胞中可抑制 IL-8, INOS 和 COX-2 的表达[1]. 0 --> CTP-NBD 相关抗体: Immunofluorescence[1] Cell Line: |
| In Vivo | CTP-NBD 在结肠炎大鼠模型中不能有效降低炎症，但改造后的 Colon-targeted CTP-NBD 具有口服活性，且可以降低结肠炎大鼠模型炎症[2]. |
| Name | CTP-NBD |
| CAS | 1268513-27-4 |
| Sequence | Tyr-Gly-Arg-Arg-Ala-Arg-Arg-Arg-Ala-Arg-Arg-Thr-Ala-Leu-Asp-Trp-Ser-Trp-Leu-Gln-Thr-Glu |
| Shortening | YGRRARRRARRTALDWSWLQTE |
| Formula | C121H194N46O32 |
| Molar Mass | 2805.12 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lee Y, et al. Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages. Eur J Pharmacol. 2014 Mar 5;726:49-56 [2]. Hong S, et al. Colon-targeted cell-permeable NFκB inhibitory peptide is orally active against experimental colitis. Mol Pharm. 2012 May 7;9(5):1310-9. |